Sakar Healthcare Ltd. (SAKAR) Share Price Near 52-Week High at Rs 957.2
- August 11, 2026
- Posted by: Harsh Piplani
- Category: News
Sakar Healthcare Ltd. Share Price is Rs 957.2, with the stock trading within 2% of its 52-week high. The company’s market capitalisation stands at Rs 2,057.34 crore.
Sakar Healthcare Ltd. Share Price stood at Rs 957.2 at the time of qualification on 11 August 2026 at 11:30:38 AM IST, with the stock trading within 2% of its 52-week high. The company’s market capitalisation was Rs 2,057.34 crore, placing it in the small-cap healthcare space while still materially larger than the median company in its industry benchmark set. For investors tracking Sakar Healthcare Ltd. Share Price Today, that combination of price proximity to a one-year high and a Rs 2,057.34 crore market value makes the stock notable in the current market scan.
The verified data confirms the price event, but it does not establish a company-specific catalyst behind the move. That matters because stocks can approach yearly highs for very different reasons, ranging from sector rotation to valuation re-rating or improving business expectations. In this case, Univest has identified a clear market event: Sakar Healthcare Ltd. Share Price is near its one-year peak, and that naturally brings valuation, profitability and peer positioning into closer focus. For readers following Sakar Healthcare Ltd. Stock News, the next step is to examine whether the supplied fundamentals and sector comparisons support the market attention.
Sakar Healthcare Ltd. Share Price Today: Within 2% of 52-Week High
| Metric | Value |
|---|---|
| LTP at 2% Qualification | Rs 957.2 |
| Market Capitalisation | Rs 2,057.34 crore |
| 52-Week High Position | Trading within 2% of its 52-week high |
Sakar Healthcare Ltd. (SAKAR) traded at Rs 957.2. Reported volume was 0.
Sakar Healthcare Ltd. Share Price Today was Rs 957.2 when the Univest screener flagged the stock at 11 August 2026 at 11:30:38 AM IST. The key point is straightforward: the stock was trading within 2% of its 52-week high, which places it close to its one-year peak without confirming a breakout or a fresh high. That distinction is important because proximity alone often attracts market interest even before a decisive move is confirmed.
For traders and long-term market participants alike, a stock near its yearly high is often screened for two reasons. First, it can reflect persistent demand and stronger relative positioning than many other counters. Second, it usually prompts a deeper review of whether valuation and operating performance justify the attention. In the case of Sakar Healthcare Ltd. Share Price, the current level of Rs 957.2 is being assessed against a company valued at Rs 2,057.34 crore, with earnings and return ratios that can now be examined against the Pharmaceuticals & Drugs industry.
Because the supplied data does not establish a direct trigger, the immediate takeaway is not about a single news catalyst but about market positioning. Stocks that move near 52-week highs tend to enter more investor watchlists, especially when sector comparisons reveal whether the premium is backed by profitability or simply by sentiment. That is why the present price context for Sakar Healthcare Ltd. Share Price leads naturally into valuation and financial-quality analysis on Univest.
Sakar Healthcare Ltd. (SAKAR) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,057.34 crore |
| P/E Ratio | 55.77x |
| P/B Ratio | 6.01x |
| ROE | 11.88% |
| ROCE | 13.16% |
| EPS | Rs 16.23 |
| Book Value Per Share | Rs 150.44 |
| Dividend Yield | 0% |
Sakar Healthcare Ltd. was valued at a P/E ratio of 55.77x, a P/B ratio of 6.01x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 11.88% and ROCE of 13.16%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs 16.23, book value per share of Rs 150.44, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 55.77x |
| Benchmark Median P/E | 18.46x |
| Benchmark Average P/E | 52.56x |
| Benchmark P/E Range | 0x to 3,396.3x |
| Company P/B Ratio | 6.01x |
| Benchmark Median P/B | 1.78x |
| Company ROE | 11.88% |
| Benchmark Median ROE | 10.21% |
| Company ROCE | 13.16% |
| Benchmark Median ROCE | 12.96% |
| Company Market Capitalisation | Rs 2,057.34 crore |
| Benchmark Median Market Cap | Rs 146.63 crore |
Sakar Healthcare Ltd. (SAKAR) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Sakar Healthcare Ltd. (SAKAR) has a P/E ratio of 55.77x, which is above the benchmark median of 18.46x, a difference of +202.11%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Sakar Healthcare Ltd. (SAKAR) has a ROE of 11.88%, which is above the benchmark median of 10.21%, a difference of +16.36%. Sakar Healthcare Ltd. (SAKAR) has a ROCE of 13.16%, which is above the benchmark median of 12.96%, a difference of +1.54%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Fredun Pharmaceuticals Ltd. | FREDUN | 2,057.67 | 45.97 | 6.87 | 11.42 | 13.15 |
| Hester Biosciences Ltd. | HESTERBIO | 2,057.85 | 15.63 | 4.68 | 16.17 | 14.12 |
| Venus Remedies Ltd. | VENUSREM-BE | 2,068.61 | 17.49 | 2.96 | 9.85 | 7.89 |
| Indoco Remedies Ltd. | INDOCO | 2,045.45 | 19.47 | 1.73 | 12.85 | 15.67 |
| NGL Fine-Chem Ltd. | NGLFINE | 2,118.6 | 44.48 | 6.5 | 27.9 | 33.91 |
Sakar Healthcare Ltd. (SAKAR) has a P/E ratio of 55.77x compared with the displayed peer median of 19.47x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.88% compares with a peer median of 12.85% across the companies shown in the table. ROCE stood at 13.16% versus the displayed peer median of 14.12%, providing a capital-efficiency comparison. Sakar Healthcare Ltd. (SAKAR) has a market capitalisation of Rs 2,057.34 crore. Among the 5 peers shown, 4 have a larger market capitalisation.
Why Investors Are Watching Sakar Healthcare Ltd.
- Sakar Healthcare Ltd. Share Price was Rs 957.2 when the stock was identified by the Univest screener as trading within 2% of its 52-week high.
- The company’s market capitalisation of Rs 2,057.34 crore places it well above the same-industry median market cap of Rs 146.63 crore.
- Valuation is elevated, with P/E at 55.77 and P/B at 6.01, both above industry medians of 18.46 and 1.78 respectively.
- Profitability remains positive, with ROE of 11.88 and ROCE of 13.16, both slightly above the same-industry medians.
- Peer comparison shows Sakar trades at a higher earnings multiple than Fredun Pharmaceuticals, Hester Biosciences, Venus Remedies, Indoco Remedies and NGL Fine-Chem.
About Sakar Healthcare Ltd.
Sakar Healthcare Ltd. is a listed company tracked under the symbol SAKAR. Based on the supplied classification, it operates in the Healthcare sector and belongs to the Pharmaceuticals & Drugs industry. That places the company within one of the more closely followed segments of the Indian market, where investors often track valuation, profitability and relative positioning across a broad listed universe.
From the available data, the company is part of an industry benchmark covering 136 companies, with a broader sector universe of 196 companies. Its market capitalisation of Rs 2,057.34 crore makes it substantially larger than the median industry participant and places it in a comparable range with several established listed pharmaceutical names included in the peer snapshot. For anyone reviewing Sakar Healthcare Ltd. Share Price, the company’s relevance in current market screens comes from this combination of industry presence, positive return ratios and a stock price that is trading close to its one-year high.
Track Sakar Healthcare Ltd. Share Price on Univest
Use Sakar Healthcare Ltd. (SAKAR) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors who want to follow Sakar Healthcare Ltd. Share Price more closely can track the stock on Univest for live price moves, 52-week levels, technical indicators, valuation ratios, profitability measures, peer comparison and sector context. Univest also helps users monitor how a stock like SAKAR is positioned on market-cap, P/E, P/B, ROE and ROCE metrics versus its industry benchmark. For readers following Sakar Healthcare Ltd. Share Price Today, that makes it easier to place daily price action alongside longer-term fundamentals instead of viewing the near-52-week-high move in isolation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Sakar Healthcare Ltd. Share Price today?
Ans. Sakar Healthcare Ltd. Share Price was Rs 957.2 at the time of qualification on 11 August 2026 at 11:30:38 AM IST. The Univest screener simultaneously identified the stock as trading within 2% of its 52-week high.
Why is Sakar Healthcare Ltd. Share Price attracting attention?
Ans. The main reason is that Sakar Healthcare Ltd. Share Price is within 2% of its 52-week high. Alongside that, the company has a market capitalisation of Rs 2,057.34 crore and positive return ratios of ROE 11.88 and ROCE 13.16.
What is the market capitalisation of Sakar Healthcare Ltd.?
Ans. Sakar Healthcare Ltd. has a market capitalisation of Rs 2,057.34 crore. In the supplied same-industry benchmark of 136 companies, that is far above the median market cap of Rs 146.63 crore and above the average of Rs 488.56 crore.
Is Sakar Healthcare Ltd. expensive compared with its industry?
Ans. On supplied valuation metrics, Sakar Healthcare Ltd. looks premium to its industry. Its P/E is 55.77 versus the same-industry median of 18.46, while its P/B is 6.01 compared with the median P/B of 1.78.
How profitable is Sakar Healthcare Ltd. based on the supplied data?
Ans. The supplied profitability metrics are positive. Sakar Healthcare Ltd. reports ROE of 11.88 and ROCE of 13.16. Both are above the industry medians of 10.21 and 12.96 respectively, though ROCE remains below the industry average of 15.62.
What do EPS, book value and dividend yield show for Sakar Healthcare Ltd.?
Ans. Sakar Healthcare Ltd. has EPS of 16.23 and book value per share of 150.44, indicating positive earnings and accounting net worth per share. The supplied dividend yield is 0, so current valuation attention is centred more on earnings and returns.
How does Sakar Healthcare Ltd. compare with similar listed peers?
Ans. Sakar Healthcare Ltd. trades at a P/E of 55.77, above Fredun Pharmaceuticals at 45.97, Hester Biosciences at 15.63, Venus Remedies at 17.49, Indoco Remedies at 19.47 and NGL Fine-Chem at 44.48.
Which sector and industry does Sakar Healthcare Ltd. belong to?
Ans. Sakar Healthcare Ltd. belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied benchmark covers 136 same-industry companies, while the broader Healthcare sector dataset referenced here includes 196 companies.
